Retatrutide (LY3437943): Structure, Research Evidence and Status

Current Batch Data

The following results are reproduced exactly as reported by Janoshik Analytical. Each sample was submitted as a blind test against three GLP-1 receptor agonists — semaglutide, tirzepatide and retatrutide — so the laboratory was not told which compound it was analysing. The identification of retatrutide is therefore the laboratory's own finding rather than confirmation of a label we supplied.

Retatrutide 10mg — batch PLB-003

Retatrutide 20mg — batch PLB-002

For general laboratory handling principles, see the Pureline Biolabs peptide reconstitution guide and reconstitution calculator.

The 10mg vial (batch PLB-003) measured 13.51mg, so that batch is filled above its stated mass. The 20mg vial (batch PLB-002) measured 18.36mg, so that batch is filled below its stated mass. We publish the measured figures rather than the labels because the two are not the same thing, and a purity percentage says nothing about how much material is in the vial. Purity and quantity are separate measurements and both are reported above.

This analysis covers identity, quantity and purity. It is not a sterility test, an endotoxin test or a stability study, and it does not constitute regulatory approval of any kind. Retatrutide is not authorised as a medicine in the United Kingdom.

Chemical Identity

What Retatrutide Is

Retatrutide is a single modified peptide designed to activate three different receptor systems: the GIP receptor (GIPR), the GLP-1 receptor (GLP-1R) and the glucagon receptor (GCGR). The scientific literature therefore describes it as a triple receptor agonist.

The informal term "GLP-3" is not scientifically correct. There is no receptor called GLP-3, and retatrutide does not act on one. The term circulates in social media and marketing but does not describe the molecule. The accurate description is a GIP, GLP-1 and glucagon triple receptor agonist.

Retatrutide Amino-Acid Sequence

The structural features that matter for identification are:

• Aminoisobutyric acid at positions 2 and 20
• Alpha-methyl-leucine at position 13
• A modified lysine at position 17 carrying the lipid side chain
• An AEEA and gamma-glutamic acid linker
• A C20 fatty diacid
• A C-terminal serinamide at position 39

The KEGG Drug record gives the backbone as YXQGTFTSDY SILLDKKAQX AFIEYLLEGG PSSGAPPPS, where X marks the two aminoisobutyric acid residues at positions 2 and 20.[8] Counting from the amidated lysine at 17, the residues run Ala¹⁸, Gln¹⁹, Aib²⁰, Ala²¹. Sequences that place the second Aib at position 21 contain an extra residue and describe a 40-residue chain, which is not retatrutide.

A plain one-letter sequence does not describe the finished compound, because it omits the two non-standard residues and the entire side chain. Identity testing should assess the finished modified peptide, not only the unmodified backbone.

Why Retatrutide Has a Lipid Side Chain

The fatty-diacid side chain promotes reversible association with albumin in biological systems, which changes the compound's pharmacokinetic behaviour compared with an unmodified short-lived peptide. In the Phase 1b study the half-life was approximately six days, which is what supports once-weekly dosing in Lilly's clinical programme.[2]

Lipidation also makes the finished molecule chemically different from a simple 39-residue peptide chain. The side chain contributes to the total molecular formula and to the expected mass. A laboratory report that identifies only an unmodified peptide backbone would not establish the identity of finished retatrutide.

Evidence by Research Level

Retatrutide has a substantial and growing clinical evidence base. Every result below belongs to Eli Lilly's investigational product, given at defined doses under medical supervision in controlled studies.

Receptor and Cellular Research

The original development paper reported that in vitro the molecule shows balanced GCGR and GLP-1R activity but more GIPR activity.[1] Relative activity therefore differs between the three receptors and depends on the assay system used.

Receptor activation does not by itself predict the size of an effect in an animal or a person. It establishes that the molecule interacts with the selected receptor systems under the stated experimental conditions.

Animal Research

In obese mice, retatrutide decreased body weight and improved glycaemic control. The paper attributed the additional weight loss to GCGR-mediated increases in energy expenditure added on top of the reduction in calorie intake driven by GIPR and GLP-1R.[1] That is the specific reason a triple agonist was pursued rather than a dual one.

Animal findings do not establish safety or efficacy in humans.

Phase 1 Research

A Phase 1 single ascending dose study in healthy participants reported a safety and tolerability profile similar to other incretins, and a reduction in body weight that persisted to day 43 after a single dose.[1]

A separate Phase 1b multiple-ascending-dose trial enrolled 72 people with type 2 diabetes over 12 weeks, comparing retatrutide against placebo and dulaglutide 1.5 mg. Pharmacokinetics were dose proportional with a half-life of roughly six days, and placebo-adjusted body-weight reduction reached 8.96 kg in the highest dose group. Gastrointestinal disorders were the most frequently reported treatment-emergent adverse events, and 29 participants discontinued early.[2]

This evidence relates to the studied clinical formulation, not to research-grade material supplied by another company.

Phase 2 Obesity Research

A Phase 2 randomised, double-blind, placebo-controlled trial published in the New England Journal of Medicine in 2023 enrolled 338 adults with obesity, or overweight plus a weight-related condition, and dosed once weekly for 48 weeks.[3]

At 48 weeks the least-squares mean change in body weight was -8.7 per cent at 1 mg, -17.1 per cent at 4 mg, -22.8 per cent at 8 mg and -24.2 per cent at 12 mg, against -2.1 per cent for placebo. Gastrointestinal adverse events were the most common, were dose-related, were mostly mild to moderate, and were partially reduced by a lower starting dose. Dose-dependent increases in heart rate peaked at 24 weeks and then declined.[3]

Phase 2 Type 2 Diabetes Research

A Phase 2 trial published in The Lancet enrolled 281 people with type 2 diabetes across 42 US centres, comparing retatrutide against both placebo and dulaglutide 1.5 mg.[4]

At 24 weeks the change in glycated haemoglobin was -2.02 per cent in the 12 mg group, against -0.01 per cent for placebo and -1.41 per cent for dulaglutide. Body weight fell by up to 16.94 per cent at 36 weeks. Mild-to-moderate gastrointestinal adverse events were reported by 35 per cent of participants in the retatrutide groups. The study did not approve retatrutide, and it says nothing about material obtained outside the clinical programme.

Phase 3 Research

By July 2026 Lilly had reported five positive Phase 3 studies. It is worth separating what has completed peer review from what has so far appeared only as a company announcement, because those are different grades of evidence.

Only TRANSCEND-T2D-1 has so far been published as a full peer-reviewed report.[5] It was a 40-week, double-blind, randomised, placebo-controlled trial at 48 sites in the USA, Mexico and India; 537 participants were randomised, 91 per cent completed treatment on study drug, and two deaths occurred, both in the 4 mg group and both judged unrelated to the study drug. The other four results come from Lilly press releases and conference presentations.[7]

Further studies remain underway in obesity, type 2 diabetes, cardiovascular disease, chronic kidney disease, sleep apnoea, osteoarthritis and liver disease.

Regulatory Status

As of September 2026 retatrutide remains investigational. It has not received FDA or MHRA approval. It has no authorised dose, no approved indication, no consumer product and no prescribing information. Lilly has stated it intends to submit retatrutide for approval in the first quarter of 2027.[6]

What Is Not Established

Pureline Biolabs does not present retatrutide as a treatment for obesity, type 2 diabetes or any other medical condition.

Current Pureline Batch

Retatrutide Testing Considerations

Retatrutide is harder to verify than a short unmodified peptide, and it is worth being explicit about why.

A high purity percentage does not prove that the main peak is retatrutide. Identity requires a separate analytical result, and for this molecule that result has to account for the lipid side chain and the two non-standard residues. A mass-spectrometry report that matches only the unmodified 39-residue backbone would be evidence of the wrong thing.

Reports may quote exact mass, average mass, charged ions or deconvoluted mass, so the displayed figure can differ from 4731.34 g/mol without indicating an error. The comparison that matters is between the reported value and the value expected for the complete modified molecule under the method used.

Retatrutide Compared With Related Compounds

Common Questions